Target Engagement and Cognitive Outcomes of Anti‐Amyloid Immunotherapies in Early‐Onset Alzheimer’s Disease: First Report from the LEADS Study
We observed excellent target engagement, with piecewise regression models showing rates of Aβ clearance comparable to those seen in Phase 3 trials. The study was underpowered to detect cognitive benefits, which are limited over a short follow-up interval. These findings underscore the utility of observational studies with biomarker data in evaluating treatment efficacy, offering insights that complement traditional randomized trials.
Authors
- Konstantinos Chiotis (ORCID: https://orcid.org/0000-0002-5679-0297)
- J. Zhang (ORCID: https://orcid.org/0000-0003-2572-2555)
- Alexandra Touroutoglou (ORCID: https://orcid.org/0000-0001-9679-2433)
- Maria Carrillo
- Dustin B. Hammers (ORCID: https://orcid.org/0000-0002-1644-2618)
- Ganna Blazhenets (ORCID: https://orcid.org/0000-0003-2419-7373)
- Ani Eloyan (ORCID: https://orcid.org/0000-0002-8110-7680)
- Piyush Maiti
- Kala Kirby
- Liana G. Apostolova
- Gil D. Rabinovici
- Brad C. Dickerson
Institutions
- Alzheimer's Association (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- University Memory and Aging Center (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_110255
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00